Penella J Woll
Woll, Penella J.
VIAF ID: 15153470791245080692 (Personal)
Permalink: http://viaf.org/viaf/15153470791245080692
Preferred Forms
- 100 0 _ ‡a Penella J Woll
- 100 1 _ ‡a Woll, Penella J.
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. | |
Angiogenic growth factor expression in benign and malignant vascular tumours | |
Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer | |
Back pain and testicular germ cell tumours | |
Breast milk in Botswana: cream and vitamin C contents | |
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer | |
CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis | |
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial | |
Cytokine Therapy | |
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro | |
Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells | |
Effects of erythropoietin on mobilisation of haemopoietic progenitor cells | |
Elevated platelet count appears to be causally associated with increased risk of lung cancer: A Mendelian randomization analysis | |
Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. | |
Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity | |
Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes | |
Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial | |
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial | |
Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development | |
Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis | |
Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. | |
Genomic tests: unreliable for cancer? A focus on circulating DNA and lung cancer | |
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk | |
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial | |
Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium | |
Lactate elimination in man: effects of lactate concentration and hepatic dysfunction | |
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes | |
Lung cancer as the presenting feature of AIDS | |
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). | |
Neuroendocrine phenotype of small cell lung cancer | |
New perspectives in lung cancer. 2. Growth factors and lung cancer | |
Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study | |
Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. | |
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. | |
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers | |
Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours | |
Pericardial effusion complicating breast cancer | |
Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis | |
Persistent back pain due to malignant lymphadenopathy | |
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. | |
A phase I trial of amsalog | |
A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin | |
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study | |
Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group | |
Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. | |
Raised serum urea predicts for early death in small cell lung cancer. | |
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer | |
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | |
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer | |
Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. | |
The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study. | |
Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour. | |
Roles for USF-2 in lung cancer proliferation and bronchial carcinogenesis. | |
The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSCC). | |
Shared heritability and functional enrichment across six solid cancers | |
Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium | |
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. | |
Suramin for breast and prostate cancer: A pilot study of intermittent short infusions without adaptive control | |
Totally implantable vascular access for long term chemotherapy | |
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. | |
Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells | |
Unbiased Detection of Somatic Copy Number Aberrations in cfDNA of Lung Cancer Cases and High-Risk Controls with Low Coverage Whole Genome Sequencing | |
Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box | |
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC) | |
The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey | |
Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients | |
Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. | |
Vascular-targeted agents for the treatment of angiosarcoma | |
Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time | |
Who treats cancer? |